Teriparatide
Treatment for Osteoporosis
Typical Dosage: 20 mcg subcutaneous injection once daily
Effectiveness
70%
Safety Score
55%
Clinical Trials
131
Participants
5.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
20 mcg subcutaneous injection once daily
Time to Effect
6-12 months
Treatment Duration
Up to 2 years lifetime maximum
Evidence Quality
HIGHNumber Needed to Treat (NNT)
11(Treat 11 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$8,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.3
Teriparatide Outcomes
for Osteoporosis
Efficacy Outcomes
Overall Effectiveness
+70%
Common Side Effects
Nausea
+9%
Leg cramps
+7%
Dizziness
+9%
Hypercalcemia
+7%
Hypotension
+2%
Active Clinical Trials
1 active trial recruiting for Teriparatide in Osteoporosis
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
NCT01155232RECRUITING
100 participants
OBSERVATIONAL
Toronto, Canada
Started: Nov 1, 2004
Completed Clinical Trials
14 completed trials for Teriparatide in Osteoporosis
A Comparison of PF708 and Forteo in Osteoporosis Patients
NCT03002428COMPLETEDPHASE3
181 participants
INTERVENTIONAL
Birmingham, United States +25 more
Started: Dec 1, 2016
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
NCT01293292COMPLETEDPHASE4
19 participants
INTERVENTIONAL
Sheffield, United Kingdom
Started: Jan 1, 2011
A Comparison Study of PF708 and Forteo in Healthy Subjects
NCT02656810COMPLETEDPHASE1
70 participants
INTERVENTIONAL
Evansville, United States
Started: Dec 1, 2015
Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
NCT00489918COMPLETEDPHASE2
165 participants
INTERVENTIONAL
Started: Jun 1, 2007
Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis
NCT00259298COMPLETEDPHASE4
12 participants
INTERVENTIONAL
London, United Kingdom
Started: Nov 1, 2005
Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
NCT00577863COMPLETEDPHASE3
200 participants
INTERVENTIONAL
Huntsville, United States +17 more
Started: Jan 1, 2008
Study of FORTEO Use in Subjects in the Community Setting
NCT01078805COMPLETED
4.17K participants
OBSERVATIONAL
Lakewood, United States
Started: Aug 1, 2003
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
NCT04747392COMPLETEDPHASE1
64 participants
INTERVENTIONAL
Guangzhou, China
Started: Aug 19, 2020
Teriparatide Treatment in Patients With Inherited Osteoporosis
NCT01360424COMPLETEDPHASE4
6 participants
INTERVENTIONAL
Helsinki, Finland
Started: May 1, 2011
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
NCT01535027COMPLETEDPHASE4
125 participants
INTERVENTIONAL
Vienna, Austria
Started: Mar 1, 2006
A Study for the Transdermal Application of Teriparatide
NCT01011556COMPLETEDPHASE2
233 participants
INTERVENTIONAL
Buenos Aires, Argentina +17 more
Started: Nov 1, 2009
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
NCT00535860COMPLETEDPHASE2
104 participants
INTERVENTIONAL
Hradec Králové, Czechia +9 more
Started: Apr 1, 2008
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
NCT00557310COMPLETEDPHASE4
35 participants
INTERVENTIONAL
Tucson, United States +5 more
Started: Nov 1, 2007
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
NCT00926380COMPLETEDPHASE2
94 participants
INTERVENTIONAL
Boston, United States
Started: Jun 1, 2009
Showing 20 of 132 total trials